Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

By Dr. Matthew Watson

Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties on net sales of commercialized products

Read more:
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

Related Post


categoriaGlobal News Feed commentoComments Off on Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor | dataNovember 22nd, 2021

About...

This author published 4072 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research